Colon cancer

The eNose Company

Better diagnostics are just a breath away

The eNose company aims to utilize the aeoNose, a portable breath analyzer, to overcome any obstacle that has thus far prevented early detection of lung cancer. Our ultimate goal is to save lives and reduce the need for expensive and invasive tests and treatments.
Being fast, painless, and a lot cheaper compared to traditional diagnostic methods (like the colonoscopy), the aeoNose can provide clarity as soon as earliest symptoms develop. The results will indicate if an additional test, a colonoscopy, is still needed.

The breath test is being used as an additional diagnostic method to the current traditional ones, in order to get a better and faster decision on the necessity for next step diagnostics.

Main advantages of the aeoNose

  • A test only takes 15 minutes
  • Ease of use

AeoNose colorectal cancer detection

The air we exhale reflects our health. Components that are released from our body through exhaled breath (Volatile Organic Compounds or VOC’s) are perfectly suited to diagnose a variety of pathologies in humans. A disease can alter the specific composition of components found in exhaled breath. Years of careful development and training of the aeoNose using ‘breath prints’ now allows us to identify, classify and predict colorectal cancer in humans.

Status of validation process on colon cancer detection

Currently, the eNose Company is finishing up a ‘multi-center validation study’, which evaluates the aeoNose for the specific application of colorectal cancer detection. This clinical study is conducted by Ms. Milou van Riswijk, PhD student and prospective gastro-enterologist. Supervisor is Prof Peter Siersema, gastro-enterologist at Radboudumc, Nijmegen, the Netherlands. Several major hospitals in the Netherlands are participating in the study including Erasmus Medical Center, Rotterdam, the Netherlands. Study results are expected to be ready over the course of 2021, hence suggesting the aeoNose most likely will be available for general use as a diagnostic tool for colorectal cancer by the end of 2021.


The reliability of the aeoNose breath test is very high as it’s critical to prevent false negative test results. Simultaneously, a rapid and early diagnosis of colorectal cancer is equally important. Results will be explained in more detail in the clinical study, conducted by Milou van Riswijk, prospective gastro-enterologist at Radboudumc, Nijmegen, the Netherlands.

Currently, we are validating the aeoNose in the following hospitals

All exhaled-breath tests are being processed in a way that preserves anonymity by encryption. Actual classifications are visible in the electronic patient file only, and therefore not accessible by The eNose Company.

Results are stored in the electronic patient file and are only available to the patient and his/her healthcare professional.

Anonymized, numerical records of all screenings are encrypted and successively stored in an international BreathPrint™ database. Newly added breathprints contribute to improved, more accurate and smarter classification algorithms. In this way, this valuable source of information on exhaled-breath analysis of detectable diseases will be available to healthcare professionals around the globe.

Currently, a breath test for general practitioners is not available yet. However, development of such a test for GPs will start soon for a number of specific indications. At the moment, any trials for a self-test have not been planned.

In case the patient shows symptoms, the general practitioner or physician should consider performing the test, pending compatibility between symptoms and approved applications of the aeoNose.

The risk of cross-contamination is negligible. The following measures are in place to ensure this:

  • For each test, a new disposable mouthpiece is used,
  • For each mouthpiece, a so-called HEPA-filter is mounted, which filters out bacteria and viruses, thereby preventing them from entering the aeoNose device.
  • The patient inhales and exhales through the (new, disposable) mouthpiece, not directly through the aeoNose. The AeoNose has been approved by departments for infection prevention in several Dutch hospitals, including in the case of Covid-19.

Related news

Aeonose breath analysis on TB screening South Africa

Aeonose breath analysis on TB screening South Africa

This year, the Union World Conference on Lung Health was held in Hyderabad, India. At the TBScience pre-conference, an official event entirely devoted to basic and translational tuberculosis (TB) research, study results were presented on the Aeonose exhaled-breath tests in Cape Town.

Just published in ‘Gut’, results from a pilot study on Barrett’s oesophagus using the Aeonose

This year, the Union World Conference on Lung Health was held in Hyderabad, India. At the TBScience pre-conference, an official event entirely devoted to basic and translational tuberculosis (TB) research, study results were presented on the Aeonose exhaled-breath tests in Cape Town.
eNose apt

Multicenter study Colon rectal cancer and advanced adenomas

Timely detection of oesophageal adenocarcinoma (OAC) and even more so its precursor Barrett’s oesophagus (BO) could contribute to decrease OAC incidence and mortality. An accurate, minimally-invasive screening method for BO for widespread use is currently not available. In a proof-of-principle study in 402 patients, we developed and cross-validated a BO prediction model using volatile organic compounds (VOCs) analysis with an electronic nose device. This electronic nose was able to distinguish between patients with and without BO with good diagnostic accuracy (sensitivity 91% specificity 74%) and seemed to be independent of proton pump inhibitor use, the presence of hiatal hernia, and reflux. This technique may enable an efficient, well-tolerated, and sensitive and specific screening method to select high-risk individuals to undergo upper endoscopy.
eNose peru

Aeonose breath analysis on TB screening Peru

The Union World Conference on Lung Health 2019 was held in Hyderabad (India) from October 30 – November 2. Dr. Ruvandhi Nathavitharana (Harvard University) presented results on the Aeonose exhaled-breath TB-study in Lima, suggesting Aeonose may meet WHO triage test criteria to rule out TB (90% sensitivity, 70% specificity) in lower-risk patients admitted with cough or TB risk factors.
international congress 2019

Improving lung cancer screening results

At the ERS Conference in Madrid (September 28 – October 2, 2019), Sharina Kort (MST, Enschede, the Netherlands) presented clinical study results on diagnosing lung cancer using the Aeonose.
Pancreas new diagnostics

Pancreas new diagnostics

Improved diagnostics for pancreatic diseases are badly needed. An electronic nose (AeoNose™) analysing exhaled breath was successfully used to distinguish between pancreas carcinoma, chronic pancreatitis (inflammation of the pancreas), and healthy controls: promising results from a multicenter pilot study in the Netherlands.
Presentations at DDW San Diego

Presentations at DDW San Diego

At the Digestive Disease Week in San Diego, 4 posters were presented discussing ongoing clinical studies with the Aeonose for exhaled-breath analysis: - Colorectal cancer and advanced adenomas - Barrett’s esophagus (presented both by Radboud University (Nijmegen, the Netherlands) and Mayo Clinic (Rochester)) - Fasting state
Aeonose breath analysis on TB screening Indonesia

Aeonose breath analysis on TB screening Indonesia

Morita Saktiawati, PhD-student working in Yogyakarta, conducted a clinical study in using the Aeonose to detect TB in exhaled breath among TB suspects. Her supervisor was Prof Tjip van der Werf from University Medical Center Groningen, the Netherlands.

Download the aeoNose user manual

The manual is intended for healthcare personnel who will be working with the aeoNose and can be downloaded free of charge.

© The eNose Company